TransCode Therapeutics, Inc. (RNAZ)
| Market Cap | 36.91M +340.5% |
| Revenue (ttm) | n/a |
| Net Income | -46.28M |
| EPS | -51.08 |
| Shares Out | 16.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,031 |
| Open | 2.240 |
| Previous Close | 2.280 |
| Day's Range | 2.090 - 2.345 |
| 52-Week Range | 2.090 - 20.990 |
| Beta | 1.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About RNAZ
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical... [Read more]
Financial Performance
Financial StatementsNews
TransCode Therapeutics Quarterly report: Q2 2026
TransCode Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
TransCode Therapeutics Transcript: AGM 2026
All proposals, including stock issuances, director elections, stock plan amendment, and auditor ratification, were approved by majority vote. No questions were raised during the Q&A session.
TransCode Therapeutics Proxy statement: Proxy filing
TransCode Therapeutics filed a proxy statement on July 17, 2026, providing details for shareholder voting and corporate governance matters.
TransCode Therapeutics Transcript: AGM 2026
The meeting was called to order, a quorum was confirmed, and the Inspector of Election was appointed. The meeting was adjourned to allow time for Nasdaq to complete its review of the company's initial listing application, with the reconvened meeting scheduled for July 20, 2026.
TransCode Therapeutics Slides: Investor presentation
TransCode Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
TransCode Therapeutics Slides: Investor presentation
TransCode Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 18, 2026.
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis BOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage on...
Transcode reports results from Phase 1a dose escalation trial with TTX-MC138
TransCode Therapeutics (RNAZ) announced further results of the Phase 1a dose escalation clinical trial. The trial met its primary endpoint of safety, with positive tolerability, combined with disease ...
TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics. B...
TransCode Therapeutics Proxy statement: Proxy filing
TransCode Therapeutics filed a proxy statement on June 2, 2026, providing details for shareholder voting and corporate governance matters.
Transcode Therapeutics initiates Phase 2a clinical trial with TTX-MC138
TransCode Therapeutics (RNAZ) announced the initiation of its Phase 2a clinical trial. The study is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in patients with circulating tumor DN...
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today ...
TransCode Therapeutics Proxy statement: Proxy filing
TransCode Therapeutics filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
TransCode Therapeutics Quarterly report: Q1 2026
TransCode Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
TransCode Therapeutics Proxy statement: Proxy filing
TransCode Therapeutics filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
Transcode Therapeutics files to sell 1.53M shares of common stock for holders
09:51 EDT Transcode Therapeutics (RNAZ) files to sell 1.53M shares of common stock for holders
TransCode Therapeutics Registration statement: Registration filing
TransCode Therapeutics filed a registration statement on May 1, 2026, providing details about a securities offering with the SEC.
Transcode Therapeutics files to sell 15.96M shares of common stock for holders
17:27 EDT Transcode Therapeutics (RNAZ) files to sell 15.96M shares of common stock for holders
TransCode Therapeutics Registration statement: Registration filing
TransCode Therapeutics filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
Transcode Therapeutics appoints Anna Moore as Chair of Scientific Advisory
TransCode Therapeutics (RNAZ) appointed Anna Moore as Chair of its Scientific Advisory Board. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in ...
Transcode Therapeutics signs research agreement with Michigan State University
TransCode announced the execution of a sponsored research agreement with Michigan State University. The agreement is designed to accelerate development of TransCode’s pipeline candidates from the labo...
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced...
TransCode Therapeutics Annual report: Q4 2025
TransCode Therapeutics has published its Q4 2025 annual report on April 15, 2026.
Transcode Therapeutics signs flexible financing agreement for up to $20M
TransCode Therapeutics (RNAZ) has entered into an agreement with an institutional healthcare investor for financing of up to $20M. The arrangement comprises pre-paid advances of up to $6M and a…
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advance...